Clin2
NCT02726555Possibly a fitRecruiting

Red yeast rice plus low-dose statin versus statin alone

DyslipidemiaAtherosclerosis

Part of Heart & circulation, Hormones & metabolism clinical trials.

This Phase 3 study compares whether taking red yeast rice plus a low-dose statin works better and is as safe as taking a standard statin alone. It aims to improve cholesterol (especially LDL) and reduce cardiovascular risk in people with mild, confirmed artery disease.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
240 people
Ages
20 years to 80 years
Study type
Interventional

Who can take part

  • You have mild artery disease shown by scans (coronary, carotid, and/or leg arteries) and your LDL “bad cholesterol” is above 70 mg/dL.
  • If you can get pregnant, you must be postmenopausal, surgically unable to become pregnant, or use two reliable contraception methods (with a negative pregnancy test).
  • You must agree to sign consent and follow study visits, blood tests, and the treatment plan.
  • Before screening, you must not have taken statins or red yeast rice products within the past 4 weeks.
  • You must not have certain serious past heart/brain/vascular events (like heart attack, stroke, unstable chest pain) or have certain planned procedures during the study.
  • You must not have significant liver or kidney problems, uncontrolled blood pressure, certain stomach ulcers, or specific hormone/gallbladder/pancreas conditions.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05365438Recruiting· Phase 4
Atorvastatin plus omega-3 for artery plaque in type 2 diabetes

This trial studies whether a combination of atorvastatin and omega-3 can reduce signs of artery plaque in people with type 2 diabetes and “mixed” cholesterol problems. It’s focused on people who don’t have symptoms from plaque yet.

Seongnam-si, Gyeonggi-do
NCT06231966Recruiting
High-dose statin combo vs. standard statin for artery disease

This trial compares a high-dose combination of rosuvastatin (a statin) and ezetimibe (another cholesterol-lowering drug) versus a standard rosuvastatin-only approach for people with peripheral artery disease (narrowed leg arteries) or widespread artery disease. The goal is to see which strategy better lowers LDL cholesterol and reduces heart and limb risks.

Seoul
NCT06186037Recruiting· Phase 4
Lower-dose combo vs. higher-dose alone for heart artery disease

This trial compares a lower-dose cholesterol pill (rosuvastatin plus ezetimibe) to a higher-dose version of just rosuvastatin for people with mild to moderate heart artery blockages who have not had a stent or bypass. It aims to see which approach works better and is safer.

Suwon, Gyeonggi-do
NCT05579626Enrolling by invitation· Phase 4
Low-dose statin plus ezetimibe vs high-dose statin for prediabetes

This trial compares two cholesterol-lowering approaches in people with prediabetes to see which one is less likely to lead to new-onset diabetes. It may help you choose a safer medication plan if you need strong cholesterol treatment to prevent future heart problems.

Bucheon-si
NCT07307989Recruiting· Phase 2
Statin plus ezetimibe vs. statin alone after stroke

This trial compares two treatments for people who recently had a stroke or TIA and have high cholesterol with artery plaque. Some participants will get a combination of two cholesterol-lowering medicines (statin and ezetimibe), while others will get only a statin.

Pozi
NCT06767774Recruiting· Phase 4
Comparing two cholesterol treatments for heart patients

This study compares two different ways of lowering cholesterol: a moderate statin (pitavastatin) plus another drug (ezetimibe) versus a stronger statin alone. The goal is to see which approach is safer regarding the risk of developing new diabetes.

Seoul

Hear when a new Dyslipidemia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.